Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 2201-2210 of 11763

Edit search filters
  1. Acoramidis Transthyretin Amyloidosis Prevention Trial In The Young (ACT-EARLY) Study In Asymptomatic Carriers Of A Pathogenic TTR Variant

    Rochester, MN

  2. Study Of Targeted Therapies For The Treatment Of Adult Participants With Moderate To Severe Crohn's Disease

    Rochester, MN

  3. Impact of Ureteral Stent and Sheaths Size on Post-Operative Pain

    Rochester, MN

  4. A Study To Assess The Safety, Tolerability, And Pharmacokinetics Of ABSK-011 In Patients With Advanced Solid Tumor

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. Peroxisome Proliferator-Activated Receptor Agonists to Prevent Primary Sclerosing Cholangitis Recurrence after Liver Transplantation

    Scottsdale/Phoenix, AZ

  6. Sacituzumab Tirumotecan (MK-2870) In Combination With Pembrolizumab Versus Pembrolizumab Alone In Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. MC230818 Understanding The Mechanisms Of Clonal And Non-clonal Cytopenia Following CAR-T Therapy

    Albert Lea, MN, Scottsdale/Phoenix, AZ, Eau Claire, WI, Jacksonville, FL, La Crosse, WI, Mankato, MN, Rochester, MN

  8. A Study Of GSK5458514 Administered Alone Or In Combination With Other Anti-Cancer Agents In Participants With Prostate Cancer

    Scottsdale/Phoenix, AZ, Rochester, MN

  9. AZD0120 In Relapsed/Refractory Multiple Myeloma (DURGA-1)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  10. Study Of Vorasidenib (AG-881) In Participants With Residual Or Recurrent Grade 2 Glioma With An IDH1 Or IDH2 Mutation (INDIGO)

    Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer